Moderna (NASDAQ:MRNA) Shares Up 5.9% - Here's Why

Key Points

• Moderna shares increased by 5.9% on Wednesday, reaching a last trading price of $27.35 after being down significantly in trading volume compared to its average.
• Analysts have set a consensus price target of $41.81 for Moderna, with ratings ranging from "Strong Buy" to "Sell" across multiple research firms.
• Moderna reported better-than-expected quarterly earnings, with an EPS of ($2.13) and revenue of $142 million, despite a 41.1% decline from the same quarter last year.

Moderna, Inc. (NASDAQ:MRNA - Get Free Report)'s share price was up 5.9% on Wednesday . The company traded as high as $27.38 and last traded at $27.35. Approximately 2,038,548 shares traded hands during mid-day trading, a decline of 81% from the average daily volume of 10,868,306 shares. The stock had previously closed at $25.83.

Analysts Set New Price Targets

Several research firms recently commented on MRNA. Morgan Stanley restated an "equal weight" rating and issued a $32.00 price target on shares of Moderna in a report on Friday, August 1st. Bank of America lowered their price objective on Moderna from $26.00 to $25.00 and set an "underperform" rating for the company in a research note on Tuesday, July 22nd. Citigroup assumed coverage on shares of Moderna in a report on Friday, August 1st. They issued a "neutral" rating and a $40.00 price objective for the company. Wells Fargo & Company reaffirmed an "equal weight" rating on shares of Moderna in a research note on Sunday, July 13th. Finally, JPMorgan Chase & Co. set a $26.00 price target on shares of Moderna in a research report on Friday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, fourteen have given a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $41.81.

Moderna Price Performance

The business has a 50 day moving average price of $26.66 and a 200 day moving average price of $27.49. The firm has a market capitalization of $10.77 billion, a P/E ratio of -3.67 and a beta of 1.93.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The company reported ($2.13) EPS for the quarter, topping analysts' consensus estimates of ($2.99) by $0.86. The company had revenue of $142.00 million during the quarter, compared to analyst estimates of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The company's quarterly revenue was down 41.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Moderna, Inc. will post -9.61 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Corient Private Wealth LLC grew its position in Moderna by 155.8% during the second quarter. Corient Private Wealth LLC now owns 56,400 shares of the company's stock worth $1,537,000 after buying an additional 34,354 shares in the last quarter. Osaic Holdings Inc. grew its holdings in shares of Moderna by 7.0% during the 2nd quarter. Osaic Holdings Inc. now owns 46,709 shares of the company's stock worth $1,289,000 after purchasing an additional 3,065 shares in the last quarter. Thrivent Financial for Lutherans grew its holdings in shares of Moderna by 600.7% during the 2nd quarter. Thrivent Financial for Lutherans now owns 92,999 shares of the company's stock worth $2,566,000 after purchasing an additional 79,726 shares in the last quarter. Marex Group plc bought a new stake in shares of Moderna during the second quarter valued at approximately $359,000. Finally, State of Wyoming acquired a new position in shares of Moderna in the second quarter valued at $94,000. Institutional investors and hedge funds own 75.33% of the company's stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.